株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

神経損傷:パイプライン分析

Nerve Injury - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 200472
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
神経損傷:パイプライン分析 Nerve Injury - Pipeline Review, H2 2016
出版日: 2016年07月13日 ページ情報: 英文 70 Pages
概要

神経損傷は神経組織の損傷で、筋肉が弱くなったり、麻痺したりします。また、皮膚のある部分の感覚が無くなったりします。症状には、立ちくらみ、便秘、膀胱機能障害、筋委縮、麻痺、ヒリヒリと焼けるような痛み、性機能障害などがあります。

当レポートでは、神経損傷の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

神経損傷 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • Acorda Therapeutics, Inc.
  • Calico LLC
  • Convergence Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Kolon Life Science, Inc.
  • Medtronic, Inc.
  • Neuralstem, Inc.
  • Neurotune AG
  • Pfizer Inc.

治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • 3K3A-APC
  • cimaglermin alfa
  • CLP-257
  • CNV-1014802
  • KLS-Nst
  • MDT-15
  • NSI-566
  • NT-1654
  • Small Molecules to Activate NAMPT for Neurological Disorders
  • Synthetic Peptides to Inhibit PDE-4A4 for Pulmonary Fibrosis and Nerve Injury
  • WAY-258131

最近のパイプライン動向

休止中のプロジェクト

開発が中止された製品

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8269IDB

Summary

Global Markets Direct's, 'Nerve Injury - Pipeline Review, H2 2016', provides an overview of the Nerve Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nerve Injury and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nerve Injury
  • The report reviews pipeline therapeutics for Nerve Injury by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nerve Injury therapeutics and enlists all their major and minor projects
  • The report assesses Nerve Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nerve Injury

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nerve Injury
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nerve Injury Overview
  • Therapeutics Development
    • Pipeline Products for Nerve Injury - Overview
    • Pipeline Products for Nerve Injury - Comparative Analysis
  • Nerve Injury - Therapeutics under Development by Companies
  • Nerve Injury - Therapeutics under Investigation by Universities/Institutes
  • Nerve Injury - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Nerve Injury - Products under Development by Companies
  • Nerve Injury - Products under Investigation by Universities/Institutes
  • Nerve Injury - Companies Involved in Therapeutics Development
    • Biogen, Inc.
    • BrainStorm Cell Therapeutics Inc.
    • Calico LLC
    • F. Hoffmann-La Roche Ltd.
    • Human Stem Cells Institute
    • Medtronic plc
    • Neuralstem, Inc.
    • Neurotune AG
    • SanBio, Inc.
    • TissueGene, Inc.
  • Nerve Injury - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 3K3A-APC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CLP-257 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MDT-15 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neovasculgen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NT-1654 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • raxatrigine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-618 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Peripheral Nerve Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Inhibit CaMKII for Stroke and Nerve Injury - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-N - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nerve Injury - Dormant Projects
  • Nerve Injury - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nerve Injury, H2 2016
  • Number of Products under Development for Nerve Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Nerve Injury - Pipeline by Biogen, Inc., H2 2016
  • Nerve Injury - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2016
  • Nerve Injury - Pipeline by Calico LLC, H2 2016
  • Nerve Injury - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Nerve Injury - Pipeline by Human Stem Cells Institute, H2 2016
  • Nerve Injury - Pipeline by Medtronic plc, H2 2016
  • Nerve Injury - Pipeline by Neuralstem, Inc., H2 2016
  • Nerve Injury - Pipeline by Neurotune AG, H2 2016
  • Nerve Injury - Pipeline by SanBio, Inc., H2 2016
  • Nerve Injury - Pipeline by TissueGene, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Nerve Injury - Dormant Projects, H2 2016
  • Nerve Injury - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Nerve Injury, H2 2016
  • Number of Products under Development for Nerve Injury - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top